Survival of patients given imatinib mesylate versus cytarabine.

Survival of 47 patients given imatinib mesylate and 133 patients given cytarabine-containing regimens as first salvage therapy for nonlymphoid blast-phase CML (2 of the 4 long-term survivors in the cytarabine group had allogeneic SCT and are alive without evidence of disease at longer than 191 and longer than 48 months).